Published in Psychopharmacology (Berl) on January 26, 2005
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets (2009) 1.30
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem (2013) 1.28
Ionotropic glutamate receptors & CNS disorders. CNS Neurol Disord Drug Targets (2008) 1.27
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Probing the allosteric modulator binding site of GluR2 with thiazide derivatives. Biochemistry (2009) 1.19
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav (2010) 1.16
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology (2007) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics (2009) 1.10
Characterizing single-channel behavior of GluA3 receptors. Biophys J (2010) 1.09
Structure of an agonist-bound ionotropic glutamate receptor. Science (2014) 1.08
Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem (2010) 0.99
High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J Biol Chem (2010) 0.98
New therapeutic targets for mood disorders. ScientificWorldJournal (2010) 0.94
Molecular mechanism of flop selectivity and subsite recognition for an AMPA receptor allosteric modulator: structures of GluA2 and GluA3 in complexes with PEPA. Biochemistry (2010) 0.94
Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol Pharmacol (2011) 0.94
Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract. PLoS One (2014) 0.93
Fetal alcohol spectrum disorders and abnormal neuronal plasticity. Neuroscientist (2011) 0.92
Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology (2012) 0.91
Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2011) 0.91
Bipolar disorder: candidate drug targets. Mt Sinai J Med (2008) 0.90
The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol (2008) 0.89
Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl) (2009) 0.88
AMPA receptor regulation at the mRNA and protein level in rat primary cortical cultures. PLoS One (2011) 0.84
Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2009) 0.83
AMPA receptor potentiators: from drug design to cognitive enhancement. Curr Opin Pharmacol (2014) 0.83
Glutamate receptor subunit expression in the rhesus macaque locus coeruleus. Brain Res (2007) 0.82
Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function? Exp Brain Res (2005) 0.81
The role of 5-HT2C receptors in touchscreen visual reversal learning in the rat: a cross-site study. Psychopharmacology (Berl) (2015) 0.81
Functional insight into development of positive allosteric modulators of AMPA receptors. Neuropharmacology (2014) 0.80
5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors. ACS Med Chem Lett (2011) 0.80
Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl) (2008) 0.80
Age-Dependent Modifications of AMPA Receptor Subunit Expression Levels and Related Cognitive Effects in 3xTg-AD Mice. Front Aging Neurosci (2014) 0.78
Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety (2011) 0.77
The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques. Neuropharmacology (2010) 0.76
Ampakine CX717 potentiates intermittent hypoxia-induced hypoglossal long-term facilitation. J Neurophysiol (2016) 0.75
Are AMPA receptor positive allosteric modulators potential pharmacotherapeutics for addiction? Pharmaceuticals (Basel) (2013) 0.75
Identification of novel modulators for ionotropic glutamate receptor, iGluA2 by in-silico screening. Theor Biol Med Model (2013) 0.75
Cyclothiazide-induced persistent increase in respiratory-related activity in vitro. J Physiol (2012) 0.75
Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One (2017) 0.75
S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. Front Pharmacol (2017) 0.75
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 8.26
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 8.10
NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol (2001) 6.96
Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science (1994) 5.21
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (2000) 4.66
Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron (1992) 4.53
Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron (1995) 4.24
A family of AMPA-selective glutamate receptors. Science (1990) 3.85
Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci (1994) 3.77
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol (1983) 3.69
Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science (1990) 3.53
Cloning by functional expression of a member of the glutamate receptor family. Nature (1989) 3.11
A new benzodiazepine pharmacology. J Pharmacol Exp Ther (2002) 2.75
Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol (1985) 2.67
Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry (1959) 2.66
Molecular cloning and functional expression of glutamate receptor subunit genes. Science (1990) 2.57
Identification of a site in glutamate receptor subunits that controls calcium permeability. Science (1991) 2.53
The biochemistry of memory: a new and specific hypothesis. Science (1984) 2.52
Light and electron immunocytochemical localization of AMPA-selective glutamate receptors in the rat brain. J Comp Neurol (1992) 2.47
Role of AMPA receptor endocytosis in synaptic plasticity. Nat Rev Neurosci (2001) 2.46
A molecular determinant for submillisecond desensitization in glutamate receptors. Science (1994) 2.43
Synaptic plasticity and AMPA receptor trafficking. Ann N Y Acad Sci (2003) 2.31
The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther (1999) 2.03
Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev (2000) 1.96
Mammalian ionotropic glutamate receptors. Curr Opin Neurobiol (1993) 1.92
AMPA receptor trafficking and long-term potentiation. Philos Trans R Soc Lond B Biol Sci (2003) 1.85
Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev (2004) 1.82
Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci (2000) 1.58
Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. Mol Pharmacol (1994) 1.51
Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron (1991) 1.45
GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today (2003) 1.44
Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci (1996) 1.36
Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci U S A (1994) 1.33
Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav (2001) 1.31
Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev (2000) 1.29
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry (1999) 1.26
Enhancement by an ampakine of memory encoding in humans. Exp Neurol (1997) 1.24
Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol (1990) 1.24
Glutamate receptor channels: novel properties and new clones. Trends Pharmacol Sci (1992) 1.23
The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature (1999) 1.21
Regulation of kinetic properties of GluR2 AMPA receptor channels by alternative splicing. J Neurosci (2000) 1.20
The role of the prefrontal cortex in higher cognitive functions. Brain Res Cogn Brain Res (1996) 1.18
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) (1999) 1.17
AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol (2004) 1.15
Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther (2003) 1.12
NMDA receptor pharmacology: perspectives from molecular biology. Curr Drug Targets (2001) 1.08
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol (2001) 1.08
Correlation between kinetics and RNA splicing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in neocortical neurons. Proc Natl Acad Sci U S A (1996) 1.05
Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol (1997) 1.05
Multideterminant role of calcium in hippocampal synaptic plasticity. Hippocampus (1994) 1.04
Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience (1999) 1.01
7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther (1995) 1.01
A centrally active drug that modulates AMPA receptor gated currents. Brain Res (1994) 1.01
The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem (2004) 1.00
Modulation of AMPA/kainate receptors by analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus. Receptors Channels (1993) 0.99
An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology (2002) 0.98
Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci (1998) 0.98
Expression of transcripts encoding AMPA receptor subunits and associated postsynaptic proteins in the macaque brain. J Comp Neurol (2004) 0.95
Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol (2002) 0.95
Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci (1998) 0.95
7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A (1995) 0.95
Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology (2001) 0.94
Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis (1998) 0.93
Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology (2002) 0.93
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology (2001) 0.93
Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol (1995) 0.92
Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl) (1982) 0.92
Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience (2004) 0.92
GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res (1997) 0.92
Selective expression of heteromeric AMPA receptors driven by flip-flop differences. J Neurosci (2004) 0.91
Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices. Neuroreport (1996) 0.91
Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr Opin Investig Drugs (2003) 0.91
A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse (1993) 0.90
LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev (2002) 0.90
New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol Ther (1996) 0.90
Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berl) (2001) 0.89
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther (2003) 0.89
The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol (1991) 0.88
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur J Pharmacol (2004) 0.87
NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol (2000) 0.85
Syndromes of schizophrenia on factor analysis. Br J Psychiatry (1992) 0.85
The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology (2004) 0.85
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol (2001) 0.85
The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment. Neuroreport (2001) 0.84
Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging (1994) 0.83
Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons. Br J Pharmacol (2000) 0.83
Stable expression of recombinant AMPA receptor subunits: binding affinities and effects of allosteric modulators. J Neurochem (1997) 0.83
AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci (1997) 0.82
Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol (1997) 0.82
Effects of intrahippocampal aniracetam treatment on Y-maze avoidance learning performance and behavioral long-term potentiation in dentate gyrus in rat. Neurosci Lett (2001) 0.82
Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res (2002) 0.82
Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology (2001) 0.81
Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Eur J Pharmacol (1993) 0.81
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther (2001) 0.81
Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther (1999) 0.80
Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea-pig hippocampal slices. Neurosci Lett (1986) 0.80
Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes. Mol Pharmacol (1992) 0.80
Expression of AMPA receptor flip and flop mRNAs in the nucleus accumbens and prefrontal cortex after neonatal ventral hippocampal lesions. Neuropsychopharmacology (2001) 0.80
Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol (1996) 0.79